$12.56
7.58% yesterday
Nasdaq, Nov 15, 10:02 pm CET
ISIN
US3968791083
Symbol
GLSI
Sector
Industry

Greenwich LifeSciences Inc Stock price

$12.56
-1.60 11.30% 1M
-2.19 14.85% 6M
+2.04 19.39% YTD
+1.58 14.39% 1Y
-22.55 64.23% 3Y
+6.81 118.43% 5Y
+6.81 118.43% 10Y
Nasdaq, Closing price Fri, Nov 15 2024
-1.03 7.58%
ISIN
US3968791083
Symbol
GLSI
Sector
Industry

Key metrics

Market capitalization $178.64m
Enterprise Value $171.42m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 30.23
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-10.76m
Cash position $7.22m
EPS (TTM) EPS $-0.81
Short interest 7.83%
Show more

Is Greenwich LifeSciences Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.

Greenwich LifeSciences Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Greenwich LifeSciences Inc:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast Greenwich LifeSciences Inc:

Buy
100%

Financial data from Greenwich LifeSciences Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses - -
-
-
- Research and Development Expense 9.13 9.13
17% 17%
-
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -11 -11
15% 15%
-
Net Profit -11 -11
17% 17%
-

In millions USD.

Don't miss a Thing! We will send you all news about Greenwich LifeSciences Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Greenwich LifeSciences Inc Stock News

Neutral
GlobeNewsWire
4 months ago
STAFFORD, Texas, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced the following update of the expansion of clinical sites into Spain.
Positive
Seeking Alpha
5 months ago
Greenwich LifeSciences, Inc. approaches enrollment completion for the phase 3 Flamingo-01 study, using GLSI-100 for the treatment of patients with HER2/neu positive breast cancer, with full enrollment expected by the end of 2024. A prior phase 2b study indicated that patients, given GLSI-100 for HER2/neu positive breast cancer, were able to achieve a 100% recurrence free rate. The global breast...
Neutral
GlobeNewsWire
5 months ago
STAFFORD, Texas, June 26, 2024 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced that it is set to join the Russell 2000 and Russell 3000 Indexes at the conclusion of t...
More Greenwich LifeSciences Inc News

Company Profile

Greenwich LifeSciences, Inc. engages in the development of a breast cancer immunotherapy designed to prevent the recurrence of breast cancer following surgery. The company was founded by Eric Rothe on August 29, 2006 and is headquartered in Stafford, TX.

Head office United States
CEO Snehal Patel
Employees 7
Founded 2006
Website www.greenwichlifesciences.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today